World's First Gene Therapy for P47 Chronic Granulomatous Disease Shows Success in Teenage Patient
Key Insights
Researchers at University College London and Great Ormond Street Hospital (search) have successfully developed and delivered the world's first gene therapy (search) for P47 chronic granulomatous disease (search), treating a 19-year-old patient named Remi in June 2024.
The treatment uses the patient's own stem cells modified with a functional copy of the NCF1 gene (search) via lentiviral vector (search), eliminating rejection risks associated with traditional bone marrow transplants.
Within weeks of treatment, the patient began producing healthy immune cells capable of fighting infections, representing a significant milestone in personalized medicine for rare genetic disorders.
Researchers at University College London (UCL) and Great Ormond Street Hospital (search) for Children (GOSH) have achieved a groundbreaking milestone in rare disease treatment by successfully developing and delivering the world's first gene therapy (search) for P47 chronic granulomatous disease (search) (CGD). The treatment was administered to 19-year-old patient Remi in June 2024, marking a significant advancement in personalized medicine for rare genetic disorders.
Revolutionary Treatment for Ultra-Rare Immune Disorder
P47 chronic granulomatous disease (search) is an inherited immunodeficiency disorder (search) affecting just one in a million people worldwide. The condition is caused by mutations in the NCF1 gene (search), which is essential for forming a key component of NADPH-oxidase (search), an enzyme responsible for killing bacteria and fungi. Without this enzyme, the immune system fails to function properly, leaving patients vulnerable to frequent fungal and bacterial infections, severe life-limiting conditions such as colitis (search) and inflammatory bowel disease (search), and potentially life-threatening complications.
The standard treatment for P47 CGD has been allogeneic haematopoietic stem-cell transplantation, commonly known as bone marrow transplant. However, finding a matching donor presents significant challenges and can be a lengthy process. Previous gene therapy (search) research had proven successful for X-CGD, a different form of chronic granulomatous disease (search), but no trials had been conducted for the P47 form until now.
Innovative Autologous Gene Therapy Approach
The new gene therapy (search) treatment involves collecting haematopoietic stem cells from the patient's own bone marrow, which are then fused with a functional copy of the NCF1 gene (search) using a lentiviral vector (search). These modified cells are subsequently administered back to the patient, delivering a functional copy of the NCF1 gene into the cells' genome.
"For the first time we've been able to develop, manufacture, and deliver a new gene therapy (search) entirely under one roof – marking a true bench-to-bedside milestone," said Professor Claire Booth, consultant paediatric immunologist at GOSH and the trial's principal investigator. "This is a significant step forward. It means that future gene therapies developed at UCL and GOSH could reach clinical trials, and patients with rare diseases like Remi, faster than ever before."
Rapid Clinical Response and Patient Impact
Within weeks of receiving the treatment, Remi began producing healthy immune cells capable of fighting infections. Unlike traditional bone marrow transplants, the autologous approach eliminates the risk of rejection since the patient's own stem cells are used.
The impact on Remi's quality of life has been transformative. "Having the gene therapy (search) has completely changed my life. I can go out and about now without worrying, help my family out and I'm excited to start university and start the next stage of my life," commented Remi, who is now 19 years old.
Integrated Development and Manufacturing Model
The P47 gene therapy (search) represents the first product to be researched, manufactured, and delivered to patients entirely within the Zayed Centre for Research into Rare Disease in Children (search), operated jointly by UCL and GOSH. This integrated approach required sophisticated viral vector manufacturing capabilities, as these vectors are highly complex to produce and their availability and effectiveness are critical determinants of clinical trial success.
In 2023, GOSH received an MHRA licence to manufacture viral vectors in the Zayed Centre. The UCL Technology Fund, managed by Albion VC in collaboration with UCL Business, funded the vector development, preclinical testing, and ongoing clinical trial. The gene therapy (search) underwent rigorous quality assurance checks before being transferred to the clinical trial delivery team for patient administration.
Future Implications and Trial Expansion
The research team plans to treat four additional children with P47 CGD as part of the ongoing clinical trial. Professor Booth emphasized the broader implications of this success: "We've demonstrated the technology works... In the future with genome sequencing at birth, you could identify a treatable condition and have personalised medicine for it."
The successful development and delivery of this gene therapy (search) under one roof could significantly accelerate the timeline for bringing future gene therapies from laboratory research to clinical application, potentially benefiting patients with other rare genetic disorders more rapidly than traditional development pathways.